Business Description
NeoGenomics Inc
NAICS : 541714
SIC : 8734
ISIN : US64049M2098
Description
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.67 | |||||
| Debt-to-EBITDA | -1381.02 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.06 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.8 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | 6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 10.43 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.01 | |||||
| 9-Day RSI | 79.44 | |||||
| 14-Day RSI | 74.6 | |||||
| 6-1 Month Momentum % | -7.63 | |||||
| 12-1 Month Momentum % | -30.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | |||||
| Quick Ratio | 1.91 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 23.32 | |||||
| Days Sales Outstanding | 79.58 | |||||
| Days Payable | 17.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.4 | |||||
| Shareholder Yield % | -0.19 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 43.54 | |||||
| Operating Margin % | -13.37 | |||||
| Net Margin % | -12.07 | |||||
| FCF Margin % | -3.35 | |||||
| ROE % | -8.38 | |||||
| ROA % | -4.69 | |||||
| ROIC % | -6.64 | |||||
| ROC (Joel Greenblatt) % | -25.83 | |||||
| ROCE % | -4.92 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 80.43 | |||||
| PS Ratio | 3.48 | |||||
| PB Ratio | 2.5 | |||||
| Price-to-Tangible-Book | 64.23 | |||||
| Price-to-Operating-Cash-Flow | 149.08 | |||||
| EV-to-EBIT | -33.88 | |||||
| EV-to-EBITDA | -5646.21 | |||||
| EV-to-Revenue | 3.84 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | -116.01 | |||||
| Price-to-Projected-FCF | 7.39 | |||||
| Price-to-Median-PS-Value | 0.92 | |||||
| Earnings Yield (Greenblatt) % | -2.95 | |||||
| FCF Yield % | -0.95 | |||||
| Forward Rate of Return (Yacktman) % | -8.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeoGenomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 590.413 | ||
| EPS (TTM) (€) | -0.559 | ||
| Beta | 1.1 | ||
| Volatility % | 50.89 | ||
| 14-Day RSI | 74.6 | ||
| 14-Day ATR (€) | 0.344944 | ||
| 20-Day SMA (€) | 14.66 | ||
| 12-1 Month Momentum % | -30.06 | ||
| 52-Week Range (€) | 11.8 - 18.6 | ||
| Shares Outstanding (Mil) | 128.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeoGenomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeoGenomics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeoGenomics Inc Frequently Asked Questions
What is NeoGenomics Inc(FRA:NG9)'s stock price today?
The current price of FRA:NG9 is €16.70. The 52 week high of FRA:NG9 is €18.60 and 52 week low is €11.80.
When is next earnings date of NeoGenomics Inc(FRA:NG9)?
The next earnings date of NeoGenomics Inc(FRA:NG9) is 2025-02-20 Est..
Does NeoGenomics Inc(FRA:NG9) pay dividends? If so, how much?
NeoGenomics Inc(FRA:NG9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers